Tag:

China

Latest Headlines

Latest Headlines

China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus

China's Guangxi Wuzhou Pharmaceutical bought a 10% stake in Israel's Oramed Pharma for $52 million as well as China rights to two diabetes treatments, Reuters reported. The deal builds on a December 2014 investment of $5 million for a 7% stake in a private placement.

Alibaba Health plans wider online sales push in China as competition heats up

Alibaba Group Holdings aims for a controlling stake in HK-listed Alibaba Health Information Technology as it seeks to grow in a still-fragmented market in China for online drug sales that increasingly looks like a tough nut to crack as competition grows and regulatory approvals drag, the South China Morning Post reports.

China aims world's fastest supercomputer at genomics

The 33.86-petaflops supercomputer, which has topped the table of the world's fastest machines since its introduction in 2013, was used to cut the time it took to detect single nucleotide polymorphisms.

China's Wuzhou says it will take 10% stake in oral insulin specialist Oramed for $52M

China's Guangxi Wuzhou Zhongheng Group disclosed that it intends to purchase a 10% stake in Israeli pharma company Oramed for $52 million, in return for exclusive Chinese distribution rights to its oral insulin following regulatory approval, according to a briefing from Reuters.

GSK's ViiV unit to work with China's Desano to make API of Tivicay for access use

The API of GlaxoSmithKline's HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drug maker's ViiV Healthcare arm, according to a press release.

Survey: Hypertension, diabetes among key rising chronic diseases in China

Hypertension afflicted 25.2% of China's adult population and diabetes 9.7%, according to the state-run Xinhua news agency. That's according to a survey conducted by the National Health and Family Planning Commission over a decade that jibes with other recent public policy healthcare reform efforts by the State Council.

Ascletis plans China, Taiwan PhIII trials on chronic hep C therapies

China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.

EU slaps Chinese amoxicillin maker with import ban

China's hit-and-miss government oversight poses special challenges for drug regulators who too often find companies there skirting the standards they expect. For the second time this year, European regulators have put a halt on exports from a Chinese company that they discovered had serious problems.

China not only source for counterfeit drugs but also for meth, other synthetics

The FDA once again pitched in last week with other international regulators to crack down on illegal and counterfeit drugs being peddled over the internet. The FDA, Interpol and other authorities seized drugs, shut down some websites and made some arrests.

Europe bans some APIs from Chinese drugmaker Zhuhai United

China's Zhuhai United Laboratories bills itself as the world's largest manufacturer of the API for the antibiotic amoxicillin. But the sterile manufacturing for some of its amoxicillin products has been called into question by inspectors in Europe, which is banning the sterile drugs for now, except in limited cases.